Cell Membrane-Coated Nanoparticles as Biomimetic Drug Delivery Systems: Design, Therapeutic Applications, and Translational Challenges.
4 affiliations
- 1Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman P.O. Box 4184, United Arab Emirates.
- 2Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.
- 3Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
- 4Department of Biomedical Sciences, College of Medicine, Gulf Medical University, Ajman P.O. Box 4184, United Arab Emirates.
Abstract
Biomimetic cell membrane-coated nanoparticles (CM-NPs) have emerged as a promising class of nanocarriers that integrate the tunable physicochemical properties of engineered nanoparticles with selected biological features of naturally derived cell membranes. By retaining membrane-associated proteins, lipids, glycans, and receptors, CM-NPs have demonstrated the potential to modulate immune recognition, prolong systemic circulation, improve biocompatibility, and facilitate disease-specific targeting; however, these effects depend on the membrane source, nanoparticle composition, coating integrity, fabrication method, and biological context. This review critically examines major membrane-engineering strategies, including lipid insertion, covalent conjugation, metabolic glycoengineering, and genetic modification, together with fabrication methods such as extrusion, sonication, electroporation, in situ polymerization, and microfluidics. Particular emphasis is placed on nanoparticles coated with erythrocyte, platelet, stem cell, immune cell, bacterial, cancer cell, and hybrid membranes. Their therapeutic applications are critically evaluated, with a primary focus on cancer therapy, including photothermal and photodynamic approaches, alongside applications in cardiovascular, neurological, infectious, inflammatory, and regenerative diseases. Recent CM-NP platforms are systematically summarized according to membrane source, therapeutic cargo or nanoparticle core, disease application, and major outcomes, while recent patents are discussed to highlight emerging technological and translational developments. Despite encouraging preclinical findings, clinical translation remains constrained by challenges in membrane isolation and purification, batch reproducibility, manufacturing scalability, preservation of membrane integrity and functionality, quality control, long-term stability, biosafety, and regulatory standardization. Advances in membrane engineering, hybrid membrane systems, scalable manufacturing, standardized characterization, and rigorous safety evaluation will be important for advancing CM-NPs toward clinical translation.
Related
- Green nanoparticles in drug delivery: Translational challenges and AI solutions
- Waste-Derived Sustainable Nanomaterials: Comprehensive Review of Synthesis Advances, Applications and Translational Challenges
- Molecular design and therapeutic applications of polymeric nanoparticles for drug delivery: A comprehensive review
- Targeted delivery of celastrol and siRNA via macrophage biomimetic nanoparticles for doxorubicin-induced cardiomyopathy therapy
- Advanced biomimetic nanomedicines for cell-based therapeutics: prospects and challenges
BibTeX
@article{jacob2026cell,
title = {{Cell Membrane-Coated Nanoparticles as Biomimetic Drug Delivery Systems: Design, Therapeutic Applications, and Translational Challenges.}},
author = {Shery Jacob and Namitha Raichel Varkey and Rekha Rao and Pottathil Shinu and Razia Khanam},
journal = {Pharmaceutics},
year = {2026},
month = oct,
doi = {10.3390/pharmaceutics18101314},
url = {https://europepmc.org/article/MED/42942844},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cell Membrane-Coated Nanoparticles as Biomimetic Drug Delivery Systems: Design, Therapeutic Applications, and Translational Challenges.
AU - Shery Jacob
AU - Namitha Raichel Varkey
AU - Rekha Rao
AU - Pottathil Shinu
AU - Razia Khanam
PY - 2026
DA - 2026/10/16
JO - Pharmaceutics
DO - 10.3390/pharmaceutics18101314
UR - https://europepmc.org/article/MED/42942844
AB - Biomimetic cell membrane-coated nanoparticles (CM-NPs) have emerged as a promising class of nanocarriers that integrate the tunable physicochemical properties of engineered nanoparticles with selected biological features of naturally derived cell membranes. By retaining membrane-associated proteins, lipids, glycans, and receptors, CM-NPs have demonstrated the potential to modulate immune recognition, prolong systemic circulation, improve biocompatibility, and facilitate disease-specific targeting; however, these effects depend on the membrane source, nanoparticle composition, coating integrity, fabrication method, and biological context. This review critically examines major membrane-engineering strategies, including lipid insertion, covalent conjugation, metabolic glycoengineering, and genetic modification, together with fabrication methods such as extrusion, sonication, electroporation, in situ polymerization, and microfluidics. Particular emphasis is placed on nanoparticles coated with erythrocyte, platelet, stem cell, immune cell, bacterial, cancer cell, and hybrid membranes. Their therapeutic applications are critically evaluated, with a primary focus on cancer therapy, including photothermal and photodynamic approaches, alongside applications in cardiovascular, neurological, infectious, inflammatory, and regenerative diseases. Recent CM-NP platforms are systematically summarized according to membrane source, therapeutic cargo or nanoparticle core, disease application, and major outcomes, while recent patents are discussed to highlight emerging technological and translational developments. Despite encouraging preclinical findings, clinical translation remains constrained by challenges in membrane isolation and purification, batch reproducibility, manufacturing scalability, preservation of membrane integrity and functionality, quality control, long-term stability, biosafety, and regulatory standardization. Advances in membrane engineering, hybrid membrane systems, scalable manufacturing, standardized characterization, and rigorous safety evaluation will be important for advancing CM-NPs toward clinical translation.
SN - 1999-4923
ER -